We have worldwide citizenship obligations. As we did with ICH, we are trying to bring everybody up to a certain level and be fit for purpose
In Conversation
The question, as we move forward with these six- and even seven-figure treatments is how the US, or any country, is going to be able to…
Overall, the industry is very different ten years down the line from the passing of the ACA, especially in terms of being much more consumer- and…
Much of the research, the development and the manufacturing that is happening in [the cell and gene therapy] space is happening right here in New Jersey
We have the unique ability and responsibility, because of our location in New York, to connect [pre-IPO biotech] companies with the financial markets and to work…
We are at the epicentre of cell and gene therapy, what we are calling ‘Cellicon Valley’. Nowhere else boasts such a concentration of cell and gene…
Recently, we have witnessed some profound policy developments that move us closer towards the holy grail of a learning healthcare system
This is both a hopeful and terrifying time to be a patient in the USA
My main focus is on accelerating clinical trials in rare disease by moving beyond “one disease at a time” approaches.
"We at ACRO have always focused on advocating for our members, as well as for our whole sector; our interest is an environment that is positive…
"Having enjoyed a highly positive start-up phase, we now need to put the right elements in place to ensure a successful phase two and continue delivering…
We are really starting to witness the advent of personalized therapies and smart missions in which there is a real convergence underway between diagnostic technologies and…
